Form 4: SOPHiA GENETICS Officer Sells Shares Under 10b5-1 Plan

SOPHiA GENETICS SA Chief Medical Officer, Philippe Menu, reported a sale of 5,000 ordinary shares under a pre-arranged trading plan.

Summary

• Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 ordinary shares on June 12, 2026.
• The sale was executed as part of a Rule 10b5-1(c) trading plan, indicating it was pre-arranged.
• The weighted average sale price was $4.9504, with individual transactions ranging from $4.81 to $5.15.
• Following the transaction, Mr. Menu beneficially owns 245,780 ordinary shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, despite the 10b5-1 plan, which can sometimes signal a lack of immediate upside confidence from management.

Negatives

• A company executive sold a portion of their holdings, which could be perceived negatively by the market, although it was conducted under a pre-arranged plan.

Risks

• The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted as a lack of confidence in the company's short-term prospects by some investors.
• The weighted average sale price of $4.9504 might indicate a price point that the executive found attractive for divestment.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Management Comments

• The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c).
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the range upon written request.

Industry Context

StockSavvy.ai notes that insider sales, even under Rule 10b5-1 plans, are closely watched by the market. While these plans are designed to avoid insider trading concerns, they can still influence investor sentiment regarding management's perception of the company's valuation and future prospects.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal of management's view on current stock valuation, potentially impacting short-term price movement.
• Employees: Similar to shareholders, may view executive sales with caution, though the 10b5-1 plan mitigates direct insider trading concerns.
• Management: Philippe Menu is executing a pre-planned divestment strategy.

Key Dates

Keywords

SOPHiA GENETICS SA, SOPH, Form 4, Insider Trading, Share Sale, 10b5-1 Plan, Philippe Menu, Chief Medical Officer, Ordinary Shares